Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Mar 11;105(10):3879-84.
doi: 10.1073/pnas.0800050105. Epub 2008 Mar 10.

Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy

Affiliations

Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy

Sarah Palmer et al. Proc Natl Acad Sci U S A. .

Abstract

Residual viremia can be detected in most HIV-1-infected patients on antiretroviral therapy despite suppression of plasma RNA to <50 copies per ml, but the source and duration of this viremia is currently unknown. Therefore, we analyzed longitudinal plasma samples from 40 patients enrolled in the Abbott M97-720 trial at baseline (pretherapy) and weeks 60 to 384 by using an HIV-1 RNA assay with single-copy sensitivity. All patients were on therapy (lopinavir/ritonavir, stavudine, and lamivudine) with plasma HIV RNA <50 copies per ml by week 96 of the study and thereafter. Single-copy assay results revealed that 77% of the patient samples had detectable low-level viremia (>/=1 copy per ml), and all patients had at least one sample with detectable viremia. A nonlinear mixed effects model revealed a biphasic decline in plasma RNA levels occurring over weeks 60 to 384: an initial phase of decay with a half-life of 39 weeks and a subsequent phase with no perceptible decay. The level of pretherapy viremia extrapolated for each phase of decay was significantly correlated with total baseline viremia for each patient (R(2) = 0.27, P = 0.001 and R(2) = 0.19, P < 0.005, respectively), supporting a biological link between the extent of overall baseline viral infection and the infection of long-lived reservoirs. These data suggest that low-level persistent viremia appears to arise from at least two cell compartments, one in which viral production decays over time and a second in which viral production remains stable for at least 7 years.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Fig. 1.
Fig. 1.
Sample selection and number of patients in the M97-720 trial included for analysis with the single-copy assay.
Fig. 2.
Fig. 2.
Decline in persistent viremia over 7 years of treatment. (A) Initial two-phase decline in viremia after the initiation of treatment for the 720 patients included in this study, as assayed by Amplicor. (B) Individual HIV-1 RNA values determined by SCA starting at week 60 (open symbols indicate negative assay values plotted at the limit of quantification). Thick black line, fitted biphasic decay model; thin gray lines, decay rates corresponding to the compartments and half-lives shown.
Fig. 3.
Fig. 3.
Individual data from six typical patients. Plasma HIV-1 RNA values (triangles) and empirical Bayes estimates of fitted individual biphasic decay curves are plotted.
Fig. 4.
Fig. 4.
Correlation between baseline plasma HIV-1 RNA and subject-specific estimates of baseline HIV-1 RNA from each compartment. Empirical Bayes estimates of individual-patient baseline HIV-1 RNA arising from compartment 3 (A) and compartment 4 (B) were computed and found to be significantly correlated with total baseline plasma viremia.
Fig. 5.
Fig. 5.
Comparison of phase 3 decay in two different studies. Analysis of longitudinal samples from 157 patients enrolled in the M97-720 (red diamonds) and M98-863 (black triangles) studies who consistently had viral RNA levels of <50 copies per ml. A statistically significant decline in HIV-1 RNA, representing a third phase of decay, was consistent between the studies (black line, M97-720; red line, M98-863). Only values obtained between 60 and 120 weeks are shown for the M97-720 study. Levels of virus above the limit of detection are shown by filled symbols, and levels below this limit are shown by open symbols plotted at the assay limit.

Similar articles

Cited by

References

    1. Dornadula G, et al. Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. J Am Med Assoc. 1999;282:1627–1632. - PubMed
    1. Havlir DV, et al. Predictors of residual viremia in HIV-infected patients successfully treated with efavirenz and lamivudine plus either tenofovir or stavudine. J Infect Dis. 2005;191:1164–1168. - PubMed
    1. Lewin SR, et al. Use of real-time PCR, molecular beacons to detect virus replication in human immunodeficiency virus type 1-infected individuals on prolonged effective antiretroviral therapy. J Virol. 1999;73:6099–6103. - PMC - PubMed
    1. Maldarelli F, et al. ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia. PLoS Pathog. 2007;3:e46. - PMC - PubMed
    1. Zhang L, et al. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N Engl J Med. 1999;340:1605–1613. - PubMed

Publication types